Integrated Graphene, the Scottish technology integration company which has pioneered a high performing, low cost, 3D Graphene Foam electrode, Gii-Sens®, for biosensing, has partnered with a world-leading team of scientists to develop a point-of-care biomedical test to revolutionise the safety of liver transplants.

A pioneering project, which aims to develop advanced sensors for use in robotic systems, could transform prosthetics and robotic limbs.

Integrated Graphene, a Scotland-based technology development and integration company, has announced plans to invest up to £8 million in scaling up its revolutionary 3D Graphene foam, Gii®, manufacturing process to meet surging global demand from the human diagnostics and energy markets.

Wearable biosensors have rapidly expanded in the consumer market but have been slow to be integrated in the healthcare setting. This could enable continuous and dynamic tracking of patient health while they are in the waiting room and provide crucial data for a triage nurse to re-prioritise patients when health can rapidly decline.

Graphene key component development and manufacturer signs sensor distribution deal with leading supplier of electrochemical goods, PalmSens.